Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 30, 2023

SELL
$57.89 - $64.73 $13.1 Million - $14.7 Million
-227,081 Reduced 98.2%
4,170 $242,000
Q2 2023

Jul 31, 2023

SELL
$63.71 - $70.74 $497,829 - $552,762
-7,814 Reduced 3.27%
231,251 $14.8 Million
Q1 2023

Apr 26, 2023

SELL
$65.71 - $74.53 $62,753 - $71,176
-955 Reduced 0.4%
239,065 $16.6 Million
Q4 2022

Jan 25, 2023

BUY
$68.48 - $81.09 $110,252 - $130,554
1,610 Added 0.68%
240,020 $17.3 Million
Q3 2022

Oct 25, 2022

SELL
$0.13 - $76.84 $59 - $35,192
-458 Reduced 0.19%
238,410 $16.9 Million
Q2 2022

Jul 27, 2022

BUY
$72.62 - $79.98 $422,285 - $465,083
5,815 Added 2.5%
238,868 $18.4 Million
Q1 2022

Apr 27, 2022

BUY
$61.48 - $73.72 $137,223 - $164,543
2,232 Added 0.97%
233,053 $17 Million
Q4 2021

Jan 25, 2022

SELL
$53.63 - $62.52 $194,891 - $227,197
-3,634 Reduced 1.55%
230,821 $14.4 Million
Q3 2021

Oct 20, 2021

SELL
$59.17 - $69.31 $86,979 - $101,885
-1,470 Reduced 0.62%
234,455 $13.9 Million
Q2 2021

Jul 27, 2021

BUY
$61.91 - $67.42 $3,219 - $3,505
52 Added 0.02%
235,925 $15.8 Million
Q1 2021

Apr 26, 2021

SELL
$59.34 - $66.74 $107,524 - $120,932
-1,812 Reduced 0.76%
235,873 $14.9 Million
Q4 2020

Jan 25, 2021

SELL
$57.74 - $65.43 $973,496 - $1.1 Million
-16,860 Reduced 6.62%
237,685 $14.7 Million
Q3 2020

Oct 22, 2020

SELL
$57.43 - $63.64 $80,804 - $89,541
-1,407 Reduced 0.55%
254,545 $15.3 Million
Q2 2020

Jul 20, 2020

BUY
$54.82 - $64.09 $2.24 Million - $2.62 Million
40,836 Added 18.98%
255,952 $15.1 Million
Q1 2020

Apr 23, 2020

BUY
$46.4 - $67.43 $9.98 Million - $14.5 Million
215,116 New
215,116 $12 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Deroy & Devereaux Private Investment Counsel Inc Portfolio

Follow Deroy & Devereaux Private Investment Counsel Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deroy & Devereaux Private Investment Counsel Inc, based on Form 13F filings with the SEC.

News

Stay updated on Deroy & Devereaux Private Investment Counsel Inc with notifications on news.